Alkeus Pharmaceuticals Receives Orphan Drug Designation From Japan's Ministry Of Health, Labour, And Welfare For Oral Gildeuretinol To Treat Stargardt Disease

Oppenheimer Maintains Outperform on Tarsus Pharmaceuticals, Raises Price Target to $100

Oppenheimer analyst Francois Brisebois maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Outperform and raises the price target from $97 to $100.

Tarsus Pharmaceuticals Q2 EPS $(0.43) Misses $(0.20) Estimate, Sales $173.912M Beat $169.677M Estimate

Tarsus Pharmaceuticals (NASDAQ:TARS) reported quarterly losses of $(0.43) per share which missed the analyst consensus estimate of $(0.20) by 115 percent. This is a 10.42 percent increase over losses of $(0.48) per

Tarsus Pharmaceuticals Announces Agreement To Acquire Alkeus For $450M Upfront In Cash And Stock, Up To $350M In Milestones, Adding Phase 3 Stargardt Disease Therapy